Smith & Nephew plc (LON:SN) Given Consensus Recommendation of “Hold” by Brokerages

Smith & Nephew plc (LON:SN) has received a consensus rating of “Hold” from the nine brokerages that are currently covering the company, Marketbeat reports. Six analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is GBX 1,310.

Several equities analysts recently issued reports on the stock. JPMorgan Chase & Co. cut their price target on shares of Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating for the company in a report on Thursday, August 6th. UBS Group reiterated a “neutral” rating and issued a GBX 1,300 target price on shares of Smith & Nephew in a research note on Tuesday, May 5th. Royal Bank Of Canada decreased their price target on Smith & Nephew from GBX 1,350 to GBX 1,250 and set a “sector perform” rating on the stock in a research report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 1,400 price target on shares of Smith & Nephew in a report on Thursday, July 30th. Finally, Citigroup lowered Smith & Nephew to a “buy” rating in a research note on Friday, July 10th.

Smith & Nephew Price Performance

Smith & Nephew stock opened at GBX 1,062.50 on Friday. The company has a debt-to-equity ratio of 73.07, a current ratio of 2.14 and a quick ratio of 0.84. The stock’s 50 day moving average is GBX 1,123.17 and its 200 day moving average is GBX 1,176.69. The company has a market cap of £11.65 billion, a P/E ratio of 38.25, a PEG ratio of 0.46 and a beta of 0.69.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.